Lucid Diagnostics Announces Pricing of Initial Public Offering
October 13, 2021 22:15 ET
|
Lucid Diagnostics Inc.
NEW YORK, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Lucid Diagnostics Inc. (Nasdaq: LUCD) (“Lucid”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq:...
PAVmed Subsidiary Lucid Diagnostics Announces Upcoming Presentation at Digestive Disease Week 2021
May 13, 2021 09:30 ET
|
PAVmed Inc.
Dr. David Poppers to present on his initial experience with Lucid’s EsoCheck and EsoGuard NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”),...
PAVmed to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference
March 10, 2021 09:30 ET
|
PAVmed Inc.
On-demand corporate presentation scheduled for March 17, 2021 NEW YORK, March 10, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly...
PAVmed Retires Convertible Debt
March 03, 2021 09:30 ET
|
PAVmed Inc.
NEW YORK, March 03, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...
PAVmed Closes $13.4 Million Common Stock Registered Direct Offering Priced At-the-Market under Nasdaq Rules
January 08, 2021 10:53 ET
|
PAVmed Inc.
NEW YORK, Jan. 08, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today...